Slate Asset Management Agrees to Acquire $226.5 Million Sunbelt Multifamily Portfolio
'We are pleased to announce our latest investment in the multifamily real estate sector – a performing portfolio of defensive assets with attractive fundamentals serving essential needs in markets with strong demographics,' said Peter Tsoulogiannis, Partner and Chief Investment Officer at Slate. 'We have strong conviction in the long-term demand for housing, and despite macro volatility, our investment philosophy remains unchanged; we continue to focus on acquiring below replacement cost with below market in-place rents in order to generate meaningful cash flow growth.'
The multifamily sector is poised to benefit from highly favorable supply-demand dynamics: a structural undersupply of new housing due to declining housing starts combined with increasing demand for rental options. The Portfolio is well occupied, with long-term growth potential through mark-to-market rent increases.
The Portfolio's garden-style apartments are concentrated in and around the growing Tampa, Atlanta, and Phoenix MSAs. The properties are located near grocers and other essential goods and service providers, providing attractive housing options for the cities' burgeoning workforces.
King & Spalding advised Slate on this transaction, which is expected to close at the end of July.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate's platform focuses on four areas of real assets, including real estate equity, real estate credit, real estate securities, and infrastructure. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more, and follow Slate Asset Management on LinkedIn, X (Twitter), and Instagram.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
13 hours ago
- Business Wire
Central Pacific Financial Corp. Announces Conference Call to Discuss Second Quarter 2025 Financial Results
HONOLULU--(BUSINESS WIRE)--Central Pacific Financial Corp. (NYSE: CPF), parent company of Central Pacific Bank, will release its second quarter 2025 earnings on July 25, 2025, before the open of the New York Stock Exchange. Management will review the results by conference call and live audio webcast beginning at 2:00 p.m. Eastern Time (8:00 a.m. Hawaii Time) on July 25, 2025. Interested parties may listen to the conference by calling 1-800-715-9871 (conference ID: 6299769), or by listening to the webcast on the company's investor relations website at A replay of the call will be available through August 24, 2025 by dialing 1-800-770-2030 (conference ID: 6299769) and on the company's website. About Central Pacific Financial Corp. Central Pacific Financial Corp. is a Hawaii-based bank holding company with approximately $7.41 billion in assets as of March 31, 2025. Central Pacific Bank, its primary subsidiary, operates 27 branches and 55 ATMs in the State of Hawaii. For additional information, please visit the Company's website at: Equal Housing Lender Member FDIC NYSE Listed CPF
Business Wire
13 hours ago
- Business Wire
Kirby McInerney LLP Urges Investors in DoubleVerify Holdings, Inc. (DV) to Inquire About Their Rights in Class Action Lawsuit
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of the July 21, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired DoubleVerify Holdings, Inc. ('DoubleVerify' or the 'Company') (NYSE:DV) securities during the period from November 10, 2023, through February 27, 2025 ('the Class Period'). [ LEARN MORE ABOUT THE CLASS ACTION ] On February 28, 2024, DoubleVerify issued lower revenue growth expectations for the first quarter of 2024 due to 'a slow start by brand advertisers and a slow ramp by recently signed new large customers.' On this news, the price of DoubleVerify shares declined by $8.25 per share, or approximately 21%, from $39.24 per share on February 28, 2024, to close at $30.89 on February 29, 2024. On May 7, 2024, in connection with its first quarter 2024 earnings report, DoubleVerify surprised analysts by cutting its full-year 2024 revenue outlook due to customers that were pulling back on their ad spending. On this news, the price of DoubleVerify shares declined by $11.79 per share, or approximately 38%, from $30.57 per share on May 7, 2024, to close at $18.78 on May 8, 2024. Then, on February 27, 2025, when DoubleVerify reported lower-than-expected fourth quarter 2024 sales and earnings due in part to reduced customer spending, DoubleVerify also disclosed that the shift of ad dollars from open exchanges to closed platforms was negatively impacting the Company. On this news, the price of DoubleVerify shares declined by $7.83, or approximately 36%, from $21.73 per share on February 27, 2025, to close at $13.90 on February 28, 2025. Finally, on March 28, 2025, market research company Adalytics Research, LLC released a report claiming that DoubleVerify's web advertisement verification and fraud protection services are ineffective, and that DoubleVerify customers are regularly billed for ad impressions served to declared bots operating out of known data center server farms. On the same day, The Wall Street Journal reported that DoubleVerify regularly misses detection of nonhuman traffic in contradiction to the Company's claims that it helps brand avoid serving ads to nonhuman bot accounts. If you purchased or otherwise acquired DoubleVerify securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@ or fill out the form below, to discuss your rights or interests with respect to these matters without any cost to you. [ CONTACT FORM ] Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
14 hours ago
- Business Wire
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation ('Quanterix' or the 'Company') (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units ('RSUs') representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company. The RSUs vest in full on the one year anniversary of the grant date, subject to the applicable individual's continued employment with the Company or one of its subsidiaries through the vesting date. About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at
